In human CB1-expressing HEK293 cells, AM251 increased forskolin-stimulated cAMP, whereas the neutral-antagonist comparator AM4113 did not. The published curves each show one assay performed in triplicate; they do not establish independent biological replication. [2]
Membrane functional profile at GPR55, CB1 and CB2
Biochemical assay · Human GPR55 expressed in HEK293s membranes; commercially supplied CB1 and CB2 receptor membranes [1]
AM251 activated GPR55 but antagonized CP55940-stimulated responses at CB1 and CB2. These are functional assay potencies, not binding affinities or treatment doses.
Literature-Reported Treatment Conditions
- Exposure duration
- 45 min
- Method
- [35S]-GTPγS binding at 30°C; antagonist activity tested against the CP55940 EC80 determined that day
- Reported limits
- Compound vehicle and supplier for AM251 are not specified in the read methods; exact screening concentration series not given in tables.
Methods and source locations
Compound reported in the paper: AM251; Compound label in the paper: AM251
Results apply to the reported research material and model; they do not validate an Adooq batch.
Tables 1–2 (AM251 rows and footnotes); Methods: Cell transfection and membrane preparation, [35S]-GTPγS binding assay; Results: GPR55 binds and is activated by cannabinoid ligands
GPR55-stimulated GTPγS binding: Membrane [35S]-GTPγS binding — Table 1, AM251 row and footnote
Maximal GPR55 GTPγS response: Membrane [35S]-GTPγS binding — Table 1, AM251 row, column heading and footnote
Inhibition of CP55940 EC80 response at CB1: Functional antagonism, not receptor-binding Ki — Table 2, AM251 row and footnote
Inhibition of CP55940 EC80 response at CB2: Functional antagonism, not receptor-binding Ki — Table 2, AM251 row and footnote
Inverse agonist response in human CB1-expressing cells
Cell-based study · Intact HEK293 cells expressing human CB1 [2]
AM251 increased forskolin-stimulated cAMP accumulation; the neutral-antagonist comparator AM4113 did not. Figure 1 shows one assay in triplicate per compound, limiting inference about independent replication.
Literature-Reported Treatment Conditions
- Exposure duration
- 5 min
- Method
- Competitive protein-binding cAMP assay at 37°C in the presence of forskolin
- Co-treatment
- Forskolin assay stimulation; AM4113 and SR141716A tested separately as comparators
- Reported limits
- Forskolin concentration and AM251 stock vehicle not specified in the read assay methods. No precise EC50 extracted from the curve.
Methods and source locations
Compound reported in the paper: AM251; Compound label in the paper: AM251
Results apply to the reported research material and model; they do not validate an Adooq batch.
Experiment 1b methods; Experiment 1 results; Figure 1b with panels a/c as comparators and caption; Drugs
Forskolin-stimulated cAMP accumulation: Competitive protein-binding assay; image viewed, no exact curve-derived maximum or EC50 adopted — Experiment 1 results; Figure 1b and caption
Direct binding to recombinant human mu-opioid receptors
Biochemical assay · Membrane homogenates from CHO cells stably expressing human MOR, without CB1 receptors [3]
AM251 displaced the MOR radioligand in a recombinant system, supporting a direct off-target binding interaction. This selected experiment measures affinity; it does not by itself establish functional antagonism or an in-vivo effect.
Literature-Reported Treatment Conditions
- Exposure duration
- 90 min
- Method
- Competition against 1 nM [3H]DAMGO at room temperature; nonspecific binding defined with 10 µM naloxone
- Co-treatment
- Radioligand-binding assay; morphine, rimonabant and AM281 were separate comparator competitors
- Reported limits
- AM251 vehicle not stated for this binding assay in the read methods. Exact concentration series is graphed, not transcribed.
Methods and source locations
Compound reported in the paper: AM251; Compound label in the paper: AM-251
Results apply to the reported research material and model; they do not validate an Adooq batch.
Methods 2.1, 2.3–2.5, 2.9; Results 3.3; Table 1 human MOR column; Figure 4/caption
Affinity at human mu-opioid receptors: Competition binding; Cheng–Prusoff conversion of IC50 to Ki as reported by authors — Results 3.3; Table 1; Figure 4 and Methods 2.9